08:03 AM EDT, 05/22/2025 (MT Newswires) -- Instil Bio ( TIL ) and ImmuneOnco Biopharmaceuticals said Thursday that they expect to complete enrollment in the mid-stage trial of their non-small cell lung cancer drug IMM2510/AXN-2510, or `2510, for multiple solid tumors in China by Q3.

The companies said they expect initial safety and efficacy data from the study, which is testing `2510 in combination with chemotherapy, in H2.

The companies said that, in parallel, they plan to begin a US phase 1b/2 trial of `2510 monotherapy in relapsed or refractory solid tumors later this year.

A late-stage trial of `2510 in combination with chemotherapy is expected to begin in mid-2026 in China, the companies said.

Shares of the company were up over 5.4% in recent Thursday premarket activity.